ReviewJournal of clinical medicine2022
Screening and Management of Dyslipidemia in Children and Adolescents.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Alliaceae versus Brassicaceae for Dyslipidemia: State of the Art and Future Perspectives. Systematic Review and Meta-Analysis of Clinical Studies.Phytotherapy research : PTR · 2024Pooled it
- Excess Weight and Dyslipidemia in Seri (Comcáac) Indigenous Children: A Cross-Sectional Study of Prevalences and Associated Factors.Epidemiologia (Basel, Switzerland) · 2026Article
- Low anemia but high dyslipidemia prevalence in Brazilian schoolchildren: a nutritional transition profile.European journal of clinical nutrition · 2026Article
- Differential Expression of microRNAs in Obese Mexican Children: Links to Insulin Resistance and Dyslipidemia.International journal of molecular sciences · 2026Observational
- Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia.Current medical science · 2026Review
- Knowledge, attitudes, and practices of Lebanese physicians on the screening of pediatric dyslipidemias: a KAP cross-sectional study.Frontiers in endocrinology · 2026Article
- XbaI polymorphism in the APOB gene and its association with increased cholesterol in children and adolescents: Ouro Preto study.Scientific reports · 2024Article
- Non-Pharmacological Treatment for Cardiovascular Risk Prevention in Children and Adolescents with Obesity.Nutrients · 2024Review
- Comparison of Two Strategies for Hypercholesterolemia Detection through Point-of-Care Testing.Diagnostics (Basel, Switzerland) · 2024Article
- Dyslipidemia in Pediatric Patients: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2023Article
- Observational
- Association of Atherogenic Index of Plasma with Cardiometabolic Risk Factors and Markers in Lean 14-to-20-Year-Old Individuals: A Cross-Sectional Study.Children (Basel, Switzerland) · 2023Article
- Genotypic and phenotypic features of dyslipidemia in a sample of pediatric patients in China.BMC pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides an overview of pediatric dyslipidemia emphasizing screening and treatment recommendations. The presence of risk factors for cardiovascular disease in childhood poses significant risk for the development of atherosclerotic cardiovascular disease and cardiovascular events in adulthood. While atherogenic dyslipidemia is the most common dyslipidemia seen in children and can be suspected based on the presence of risk factors (such as obesity), familial hypercholesterolemia can be found in children with no risk factors. As such, universal cholesterol screening is recommended to identify children with these disorders in order to initiate treatment and reduce the risk of future cardiovascular disease. Treatment of pediatric dyslipidemia begins with lifestyle modifications, but primary genetic dyslipidemias may require medications such as statins. As pediatric lipid disorders often have genetic or familial components, it is important that all physicians are aware that cardiovascular risk begins in childhood, and can both identify these disorders in pediatric patients and counsel their adult patients with dyslipidemia to have their children screened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.